Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 9/20 | 0.75 |
| ▸ | DBF4 | Q9UBU7 | 9/20 | 0.75 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28885517 | 0.99 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| Bromide SCHEMBL28376005 | 0.99 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL892889 | 0.90 | CDC7 (0.77) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL2885708 | 0.87 | TRPM8 (0.78) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL4464882 | 0.87 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL2085303 | 0.87 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL289229 | 0.87 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL2823339 | 0.87 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL2885887 | 0.87 | TRPM8 (0.78) | CDC7DBF4TRPM8MAPTKDM4E | |
| SCHEMBL14394992 | 0.87 | CDC7 (0.73) | CDC7DBF4TRPM8MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192281-A | Febuxostat Process for the preparation of intermediates | 潍坊市海欣药业有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-111039891-B | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-111072591-B | Febuxostat and intermediates and synthesis thereof | 杭州朱养心药业有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-118994140-A | Triazole derivative with antidepressant effect, and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118994141-A | Phenylthiazole derivative with anti-liver cancer and anti-inflammatory activities and preparation method and application thereof | 河南科技大学 | 2024-11-22 | — | — | CN | claimed |
| CN-117924211-A | Preparation method of febuxostat | 哈药集团技术中心 | 2024-04-26 | — | — | CN | claimed |
| CN-112961119-A | Preparation method of febuxostat impurity | 廊坊师范学院 | 2021-06-15 | — | — | CN | claimed |
| CN-111499593-A | Synthesis process of febuxostat | 峨眉山宏昇药业股份有限公司 | 2020-08-07 | — | — | CN | claimed |
| CN-111072591-A | Febuxostat, intermediate and synthesis thereof | 杭州朱养心药业有限公司 | 2020-04-28 | — | — | CN | claimed |
| CN-111039891-A | Method for synthesizing febuxostat and intermediate thereof | 杭州朱养心药业有限公司 | 2020-04-21 | — | — | CN | claimed |
| CN-109354584-A | The method of one pot process 2- (4- hydroxy phenyl) -4- methyl-1,3-thiazole-5-carboxylic acid ethyl ester | 湖北理工学院 | 2019-02-19 | — | — | CN | claimed |
| WO-2016046836-A2 | A NOVEL PROCESS FOR PREPARATION OF ETHYL 2-(4-HYDROXY-3-NITROPHENYL)-4-METHYL-5-THIAZOLECARBOXYLATE | EXCEL INDUSTRIES LTD. (IN) | 2016-03-31 | — | — | WO | claimed |
| EP-1651624-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED THIAZOLES | ABBVIE INC (US) | 2015-03-11 | — | — | EP | claimed |
| US-20140112992-A1 | PROCESS FOR FEBUXOSTAT | HETERO RESEARCH FOUNDATION (IN) | 2014-04-24 | — | — | US | claimed |
| EP-2718272-A2 | PROCESS FOR FEBUXOSTAT | Hetero Research Foundation (IN) | 2014-04-16 | — | — | EP | claimed |
| WO-2012168948-A2 | PROCESS FOR FEBUXOSTAT | HETERO RESEARCH FOUNDATION (IN) | 2012-12-13 | — | — | WO | claimed |
| WO-2012131590-A1 | AN IMPROVED PROCESS FOR PREPARATION OF FEBUXOSTAT AND ITS POLYMORPHIC CRYSTALLINE FORM C THEREOF | SANDOZ AG (CH) | 2012-10-04 | — | — | WO | claimed |
| CN-102002017-B | Method for preparing febuxostat intermediate | BEIJING SECOND PHARMACEUTICAL CO LTD | 2012-09-26 | — | — | CN | claimed |
| CN-121974867-A | Synthesis method and application of febuxostat key intermediate | 浙江理工大学 | 2026-05-05 | — | — | CN | disclosed |
| US-20050027128-A1 | Substituted thiazoles | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027128-A1 | Substituted thiazoles | XDH, TH, TPI1 | CDC7 3048/4885DBF4 1771/4885TRPM8 2914/4885 |
| US-20140112992-A1 | PROCESS FOR FEBUXOSTAT | FIP1L1, FH, FIBP | CDC7 4490/4885DBF4 2831/4885TRPM8 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.